Status:
UNKNOWN
Observational Study on Patients With Hepatocellular Carcinoma (HCC)
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
16+ years
Brief Summary
This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in L...
Eligibility Criteria
Inclusion
- Clinical diagnosis of HCC;
- Age ≥ 16 years;
- Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;
- Good compliance with clinical treatment.
Exclusion
- Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer;
- Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days;
- HCC diagnosed after liver transplantation;
- Poor compliance or important data deficient.
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04021056
Start Date
January 1 2011
End Date
December 31 2022
Last Update
July 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital
Guangzhou, Guangdong, China